Engflag

Andol blue

Quick links to important sections

Andol blue

Andol blue_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Andol blue

What is Andol blue? Defining its Identity and Class

Property Description
Active ingredient Paracetamol (Acetaminophen)
Form Oral tablets, Effervescent tablets
Pharmacological class Non-Opioid Analgesic, Antipyretic
Common use Relief of mild-to-moderate pain and fever
Origin Synthetic

Andol blue is a medicinal preparation classified as a non-opioid analgesic and antipyretic, designed for the symptomatic relief of pain and fever. This places it in the high-level pharmacological category of simple analgesics. The drug is identified by its single active constituent, Paracetamol (commonly known as Acetaminophen), which is a synthetic compound. Paracetamol is an established first-line treatment for acute pain and fever in many clinical settings. The medication is clinically recognized for its efficacy in rapidly lowering elevated body temperature, making it suitable for common complaints like headaches or generalized aches associated with a cold.

Composition and Formulation: The Role of Paracetamol and Key Differentiation

The therapeutic action of Andol blue relies exclusively on its single, core ingredient, Paracetamol, making it a monotherapy product free of unnecessary co-active substances. This active ingredient is presented in common oral dosage forms, which primarily include traditional oral tablets and sometimes rapidly-dissolving effervescent tablets. The effervescent preparation is a key feature, distinguishing it from standard formulations and often marketed for its speed of onset, attributed to the faster absorption rates of liquid formulations. Paracetamol acts primarily in the central nervous system to reduce pain signals and influence the brain’s temperature-regulating center. This selective central action means the medicine works in the brain and spinal cord to help reduce the sensation of pain and lower a high temperature, distinguishing it from drugs that primarily target peripheral inflammation.

Regulatory References

  1. MedlinePlus, National Institutes of Health

What side effects are possible with Andol blue?

Possible side effects and safety information

The safety profile of Andol blue (Paracetamol/Acetaminophen) is officially documented by regulatory agencies and classified into specific adverse reaction categories. The primary concern established in regulatory documents is the potential for hepatotoxicity (liver damage), which is dose-dependent and the central risk, especially in cases of acute overdose.

Adverse effects are categorized within System-Organ Classes (SOCs). The Hepatobiliary disorders SOC is critical, as is the Skin and subcutaneous tissue disorders class, which includes documentation of rare but severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Other adverse events, such as serious Blood and lymphatic system disorders (e.g., thrombocytopenia), are also documented but often classified as Rare or Very Rare according to official frequency frameworks. The regulatory documentation provides explicit safety constraints regarding use in high-risk populations. The medicine is often contraindicated in individuals with severe hepatic impairment, and caution is advised for those with severe renal impairment or chronic alcohol use, as these factors increase the documented risk of toxicity.

Official Safety Domains

Domain Key Regulatory Focus
Seriousness Tier Acute Liver Failure/Hepatotoxicity
Organ System Hepatobiliary disorders; Skin and lymphatic system disorders
Contextual Risk Risks associated with acute overdose and long-term cumulative exposure
High-Risk Population Patients with Severe Hepatic Impairment

This framework ensures that all documented risks, including those related to dosage limits and underlying patient conditions, are formally communicated to define the boundaries of the drug’s safe use profile.

Overdose and Emergency Response

Overdose of Andol blue, which contains Paracetamol (Acetaminophen), is classified as a medical emergency due to the risk of severe, potentially fatal hepatotoxicity (liver damage), as stated in regulatory documents. Immediate action is mandated in all suspected cases.

Documented Overdose Presentations

Symptoms are often delayed and non-specific, which complicates assessment. Early manifestations (first 24 hours) may include nausea, vomiting, anorexia, diaphoresis (sweating), and generalized malaise. The absence of these initial symptoms does not preclude severe toxicity.

Later, life-threatening outcomes are driven by acute hepatic failure, which can involve hepatic necrosis, metabolic acidosis, hypoglycemia, and coagulopathy. Renal tubular necrosis and cardiac arrhythmias are also documented complications.

When and How to Seek Help

Official regulatory guidance requires individuals to seek immediate medical attention and contact a poison control center or emergency services without delay, even if the person appears well. This urgency is critical because the specific antidote, N-acetylcysteine (NAC), is required to prevent liver damage. Its maximum protective effect is achieved when administered within the first 8 hours following ingestion.

Management procedures, as described in official documents, necessitate prolonged hospital observation for a minimum of 48 hours and the monitoring of plasma Paracetamol concentrations. Individuals with pre-existing hepatic impairment or chronic alcoholism are noted to be at increased risk of severe toxicity.

Therapeutic Uses of Andol blue

What Andol blue treats: Main Uses and Benefits

Andol blue is generally used in symptomatic management, applied across therapeutic domains where acute physical discomfort and elevated body temperature may interfere with general well-being. Its therapeutic utility supports patients in achieving short-term symptomatic support and helps maintain a sense of stability when symptoms become more noticeable. The active ingredient is commonly used to help with temporarily relieving pain and reducing fever.

This medication is relevant for easing mild-to-moderate pain and is commonly used across conditions presenting with acute episodes. The primary symptom clusters addressed include symptoms related to physical discomfort, such as tension headaches, muscle aches, toothache, and episodic manifestations like menstrual pain, alongside symptoms related to systemic imbalance, such as fever (pyrexia) and general malaise often seen with influenza-like illnesses. Short-term symptomatic assistance is needed in these scenarios.

“This supportive role provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.”

Quick Facts

Quick Fact: Therapeutic Use Description
Symptom Domains Helps address symptom clusters that may become disruptive, including acute pain and fever.
Use Context Applied in scenarios where additional management of discomfort is required during episodic or acute symptom flare-ups.
Patient Benefit Provides supportive relief when symptoms interfere with routine activities and supports general well-being.

Eligibility and Restrictions for Use

Andol blue (Paracetamol/Acetaminophen) is restricted to certain patient groups based on official regulatory labeling. Use is absolutely contraindicated in individuals with a known hypersensitivity to the drug or any component, and in patients diagnosed with severe active liver disease or severe hepatic impairment.

The medicine is generally established for use in adults, adolescents, and older adults. Pediatric use is conditional: while permitted, the 500 mg strength is typically not suitable for children below a specific age or weight due to precise dosing requirements. The regulatory status of 'use not established' applies to some specific applications in patients younger than two years.

The official profile mandates conditional use under several specific circumstances. Caution is required for patients with severe renal impairment (creatinine clearance le 30 mL/min), chronic alcoholism, chronic malnutrition, or severe hypovolemia. Regarding reproductive status, use during both pregnancy and lactation is generally permitted when clinically necessary, provided it is managed at the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

Andol blue (Paracetamol/Acetaminophen) exhibits documented interaction patterns that are classified based on their official effect on drug activity, clearance, or toxicity risk, as detailed in regulatory sources.

Pharmacodynamic Interactions

The most significant documented interaction is with oral anticoagulants. Regular, prolonged daily use of Paracetamol can formally enhance the anticoagulant effect of Coumarin derivatives, such as Warfarin. This officially increases the risk of bleeding and necessitates increased monitoring of the International Normalized Ratio (INR) during co-administration.

Metabolic and Toxicity Risk

Co-administration with hepatic enzyme-inducing substances is associated with an increased official risk of hepatotoxicity (liver damage). This category includes medicinal products like Rifampicin and certain antiepileptic drugs (e.g., Phenytoin, Carbamazepine). The herbal product St. John's Wort and regular excessive alcohol consumption are similarly documented as enzyme inducers that heighten this organ-specific risk, especially in populations with prior alcoholism.

Exposure Alterations and Timing Rules

The absorption rate of Paracetamol is accelerated by co-administration with Metoclopramide or Domperidone, potentially increasing peak concentration. Conversely, Cholestyramine reduces Paracetamol absorption. This reduction mandates a formal timing separation rule: administration of the two substances must be separated by at least one hour. Probenecid is also officially documented to reduce the clearance of Paracetamol, while Zidovudine co-administration enhances the tendency to neutropenia.

Mechanism of Action

Andol blue is identified as a product containing acetylsalicylic acid (aspirin), which acts as an irreversible inhibitor of the cyclooxygenase (COX) enzymes, COX-1 and COX-2.

Acetylsalicylic acid is systemically absorbed and is rapidly hydrolyzed to salicylic acid. The acetyl group of the molecule is transferred to the Serine 530 residue within the active site of the COX enzyme, leading to a stable covalent modification. This acetylation permanently blocks the enzyme's capacity to convert arachidonic acid into prostaglandin H2 (PGH2).

In the peripheral tissues, this inhibition curtails the intracellular production of prostanoids, which modulates local signaling. Specifically, within platelets, COX-1 inhibition prevents the formation of thromboxane A2 (TXA2), a critical eicosanoid that mediates platelet aggregation. This reduction in TXA2 formation alters the system-level physiological process of hemostasis by decreasing platelet activity and prolonging the bleeding time.

Dosage and Administration Information

The application of Andol blue is defined by clinical guidelines that govern its oral administration and dosing schedule. This medication is indicated for oral administration in standard tablet and effervescent forms. The effervescent preparation carries a specific instruction: it must be fully dissolved in a glass of water before ingestion. The medication may be taken with or without food.

The standard single adult dose is 500 mg to 1000 mg, administered as required, with an absolute minimum interval of four hours between doses. The total intake from all sources in a 24-hour period must not exceed the established maximum daily dose of 4000 mg. This ceiling requires users to avoid concurrent use of any other products containing paracetamol/acetaminophen. Use is intended for short-term management and should generally not exceed three consecutive days.

Specific population rules mandate adjustments to the standard schedule. For individuals with renal impairment, the dosing interval must be prolonged to six or eight hours, depending on the degree of impairment. Similarly, patients with hepatic impairment or those with chronic alcoholism must reduce their maximum total daily dose, typically not exceeding 2000 mg per day. These instructions ensure the application of the medicine within the boundaries defined by established therapeutic standards.

Recent Clinical Evidence

Evidence for Use in Acute Mild-to-Moderate Pain

The research base for the active substance in Andol blue includes numerous Randomized Controlled Trials (RCTs). These studies explored how symptoms change over a defined time interval. Researchers examined outcomes related to physical discomfort in non-hospitalized adults experiencing episodes of pain, such as headaches and short-term post-operative pain. Studies explored patient-reported outcomes describing perceived discomfort and the time to initial reported change in discomfort. Findings describe patterns observed in the studies related to short-term symptomatic change. However, research provides limited information for long-term outcomes regarding use over extended periods. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Evidence for Use in Fever (Pyrexia)

Clinical research for the use of Andol blue in fever was evaluated in trials assessing short-term or episodic symptom patterns associated with elevated body temperature. These RCTs examined temporary physiological imbalance in both adult and pediatric populations. The research examined outcomes related to systemic or functional imbalance, with the main focus being the measurement of objective changes in body temperature. Trials monitored the time required for changes in temperature. What remains uncertain is the impact of this symptomatic intervention on the overall course of the underlying condition that caused the fever. Long-term effects are not fully established, as the follow-up durations were limited.

Evidence Gaps and Limitations

Research has explored the substance in various subgroups, including children experiencing fever, which is foundational to the medicine's regulatory evaluation. However, the results apply only to the populations studied, and data for certain groups, like older adults with complex health states, remain insufficient in the broader context. A key limitation is that the existing research base provides limited insight into the efficacy structure for pain that is complex or chronic, and most evidence is characterized by exploring short-term symptom changes rather than long-term stability.

Key Studies & References National Institutes of Health (NIH) MedlinePlus: Acetaminophen Information

Frequently Asked Questions (FAQ)

Common questions about Andol blue (FAQ)

Q: Can I take it for migraines?

A: Official product information usually specifies the types of pain the medicine is approved to treat, which commonly includes general headache. While the regulatory labeling may not specifically use the term 'migraine' unless a formulation is explicitly approved for it, the label typically describes the types of pain the medicine is approved to treat, which helps inform its use for various painful conditions.

Q: Does it make you sleepy?

A: Regulatory documents list potential side effects, including those affecting the central nervous system (CNS). Adverse reactions such as dizziness or drowsiness may be included in the official safety information. These effects are what might be reported by patients experiencing sleepiness.

Q: Is it safe long-term?

A: Official drug labels contain important Warnings and Precautions regarding the use of the medicine for prolonged periods. They detail potential risks associated with use for longer than directed. Official warnings outline specific risks to the heart, stomach, or kidneys that have been associated with prolonged use, indicating the safety limitations for long-term administration.

Q: Can children 2 years old use it?

A: For specific pediatric formulations, official regulatory documents provide clear guidelines regarding use in younger children. The official information either lists specific dosing instructions for children aged 2–3 years or indicates that use in this age group should be discussed with a healthcare professional. Information regarding specific age instructions can be found on the product label.

How should Andol blue be stored and disposed of?

Official Storage and Disposal Requirements

Andol blue (Paracetamol/Acetaminophen tablets) must be stored strictly according to its official labeling to ensure stability and safety. The product should be kept at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F). Storage must protect the tablets from moisture, excessive heat, and light, especially for moisture-sensitive formulations like effervescent tablets; do not store the medicine in a bathroom.

The product must remain in its original container, which should be kept tightly closed when not in use. A mandatory storage requirement is to keep the medicine out of the sight and reach of children to prevent accidental poisoning.

For disposal, unused or expired medication should be taken to an official drug take-back program or pharmacy collection point. It is strictly recommended not to dispose of the tablets by flushing them down the toilet or pouring them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Andol blue found in:

A-Z Index: